Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Penumbra Inc

Get SEC filing alerts via email and in your feed for Penumbra Inc

PEN

Penumbra Inc

About Penumbra Inc

Penumbra, Inc. develops innovative medical devices for treating vascular and neurovascular conditions, including thrombectomy, embolization, and access products. Its portfolio targets stroke, pulmonary embolism, aneurysms, and other blood vessel disorders, primarily serving healthcare providers worldwide. The company emphasizes proprietary technology, regulatory compliance, and clinical research to deliver safe, effective, and cost-efficient solutions in endovascular therapy.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Penumbra Inc

1
1
Penumbra Inc Penumbra Reports $374.8 Million Revenue in Q1 2026, 15.6% Increase Year-Over-Year

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Penumbra Inc Penumbra Reports 17.5% Revenue Growth to $1.4 Billion, Announces Merger with Boston Scientific

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Penumbra Inc Penumbra Reports 17.8% Revenue Growth to $354.7 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Penumbra Inc Penumbra Reports 13.4% Revenue Growth to $339.5 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Penumbra Inc Penumbra Reports 16.3% Revenue Growth to $324.1 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Penumbra Inc Penumbra Reports $1.19 Billion Revenue for Fiscal Year 2024, 12.9% Increase

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Penumbra Inc Penumbra, Inc. Reports 11.1% Revenue Growth, Net Loss Due to Impairment Charge in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments